ArticleRetrovirology2019

Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.

Tumelo Moshoette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.